Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q1 2024 Earnings Presentation
12 slides from Bactiguard Holding Ab's earnings presentation, Apr 25, 2024
Slide 1: Q1 2024 presentation
Q1 2024 presentation Thursday 25 April 2024 Christine Lind, CEO Patrick Bach, CFO
Slide 2: Q1 2024: Strategic transformation concluded and new leadership in place
Q1 2024: Strategic transformation concluded and new leadership in place
Slide 3: Strategic transformation concluded
Strategic transformation concluded On track to deliver cost savings, on a yearly basis, exceeding SEK 25 million License R&D and coating development BIP portfolio - strengthen organization - BD agreement - double down on - institutionalize - transition/phase out current partnerships - Billy Söderval
Slide 4: Collaboration with BD strengthened further in Q1
Collaboration with BD strengthened further in Q1 In partnership since 1995 – longest and strongest Recap • Significant global market value for Foleys ~USD 1.5bn, annual growth ~5%* • Exclusive global license for Bactiguard coated Foley catheters (ex China), agreement from December 2023 • Limited imp
Slide 5: Continued progress in Zimmer Biomet partnership
Continued progress in Zimmer Biomet partnership Recap • Global leader in orthopedics • Two agreements: trauma implants (2019) and multiple product segments (2022) • “Let’s talk about infections” theme 2023 Q1 highlights • European ZNN Bactiguard rollout continues – strong recognition and demand, slo
Slide 6: Key figures and events Q1 2024
Key figures and events Q1 2024 Strategic transformation concluded and new leadership in place Key figures Q1 2024 (Q1 2023) Key events in Q1 • Agreement with Dentsply Sirona not to pursue Revenues 58.8 (61.2) MSEK the application development project further due to changed priorities at Dentsply Siro
Slide 7: New revenue reporting streams
New revenue reporting streams 7
Slide 8: Total revenue Q1 2024
Total revenue Q1 2024 • Total license revenue amounted to SEK New split of net sales 35.1 (39.4) million, a decrease of SEK 4.2 million, corresponding to 11.2 percent adjusted for currency effects. • Revenues from BD amounted to SEK Jan-Mar Full year RTM 28.0 (36.3) million, a decrease of SEK MSEK 2
Slide 9: Total operating costs and cash flow Q1 2024
Total operating costs and cash flow Q1 2024 On track to deliver cost savings exceeding SEK 25 million on a yearly basis following the transformation Total operating costs Total cash flow • Costs for raw materials and consumables • Cash flow from operating activities amounted amounted to SEK -11.5 (-
Slide 10: Opportunities behind critical global healthcare trends
Opportunities behind critical global healthcare trends The issues The market opportunity (USD 80bn) • Antimicrobial resistance one of the top global public health threats facing humanity – associated with the Orthopedics 40 death of close to 5 million people globally in 2019 • 1 in 10 patients world
Slide 11: Q&A
Q&A Q&A to champion a healthier world by preventing infections 11
Slide 12: Questions & Answers
Questions & Answers Q1 2024 presentation Christine Lind Patrick Bach CEO CFO 12